SEC Filings

SEC Filings

Filing date	Description	Form	View
Oct 30, 2019	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-19-057797.pdf 0001104659-19-057797.rtf 0001104659-19-057797.xls
Oct 28, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-006665.pdf 0001214659-19-006665.rtf 0001214659-19-006665.xls
Oct 28, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-006666.pdf 0001214659-19-006666.rtf 0001214659-19-006666.xls
Oct 28, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-006667.pdf 0001214659-19-006667.rtf 0001214659-19-006667.xls
Oct 28, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-006668.pdf 0001214659-19-006668.rtf 0001214659-19-006668.xls
Oct 28, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-006669.pdf 0001214659-19-006669.rtf 0001214659-19-006669.xls
Oct 28, 2019	Statement of changes in beneficial ownership of securities	4	View HTML 0001214659-19-006670.pdf 0001214659-19-006670.rtf 0001214659-19-006670.xls
Oct 24, 2019	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-19-056122.pdf 0001104659-19-056122.rtf 0001104659-19-056122.xls
Oct 18, 2019	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	View HTML 0001104659-19-054951.pdf 0001104659-19-054951.rtf 0001104659-19-054951.xls
Oct 01, 2019	An amendment to the SC 13G filing	SC 13G/A	View HTML 0000921895-19-002479.pdf 0000921895-19-002479.rtf 0000921895-19-002479.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE